CD274 and head and neck squamous cell carcinoma: For contextual purposes, the single-arm Phase IV KEYNOTE-B10 clinical trial, which investigated first-line pembrolizumab combined with carboplatin and paclitaxel in R/M-HNSCC, reported an ORR of 49% and a DCR of 75%, with an ORR of 44% in patients with PD-L1 CPS ≥ 20 (19).